CHCWM – Cancer & Hematology Centers of West Michigan

IK-175-001 (Ikena)

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma